Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically modified cells and then applies them in research and clinical applications that advance human health. Horizon has an international customer base of over 1,400 unique organisations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into a range of markets, estimated to be worth over £29 billion in 2015.